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RESEARCH ARTICLE
Imatinib prevents beta cell death in vitro but does not improve islet
transplantation outcome
Aileen J. F. Kinga, Lisa A. Griffithsa, Shanta J. Persauda, Peter M. Jonesa, Simon L. Howella and Nils Welshb
aDiabetes Research Group, Division of Diabetes and Nutritional Sciences, King’s College London, London, United Kingdom;
bDepartment of Medical Cell Biology, Uppsala University, Biomedicum, Uppsala, Sweden
ABSTRACT
Introduction Improving islet transplantation outcome could not only bring benefits to individual
patients but also widen the patient pool to which this life-changing treatment is available. Imatinib has
previously been shown to protect beta cells from apoptosis in a variety of in vitro and in vivo models.
The aim of this study was to investigate whether imatinib could be used to improve islet transplant-
ation outcome.
Methods Islets were isolated from C57Bl/6 mice and pre-cultured with imatinib prior to exposure to
streptozotocin and cytokines in vitro. Cell viability and glucose-induced insulin secretion were measured.
For transplantation experiments, islets were pre-cultured with imatinib for either 72 h or 24h prior to
transplantation into streptozotocin-diabetic C57Bl/6 mice. In one experimental series mice were also
administered imatinib after islet transplantation.
Results Imatinib partially protected islets from beta cell death in vitro. However, pre-culturing islets in
imatinib or administering the drug to the mice in the days following islet transplantation did not
improve blood glucose concentrations more than control-cultured islets.
Conclusion Although imatinib protected against beta cell death from cytokines and streptozotocin in
vitro, it did not significantly improve syngeneic islet transplantation outcome.
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Introduction
Strategies to improve islet transplantation as a therapy for
type 1 diabetes have been extensively studied by research
groups across the world, including Uppsala University
(1–16) and King’s College London (17–25). The advantages
are apparent; improving islet transplantation outcome could
not only bring benefits to individual patients but also
widen the patient pool to which this life-changing treat-
ment is available. The foundation on which such strategies
are built is thorough knowledge of islet biology. This is the
legacy of Professor Claes Hellerstr€om and the common
interest which has led to collaborations between King’s
College London and Uppsala University spanning the last
40 years (17,26–31). In the current collaboration we have
studied the effect of imatinib mesylate (imatinib) on islet
transplantation outcome which builds on data generated by
the Department of Medical Cell Biology, Uppsala (32–37).
Imatinib is an inhibitor of the non-receptor tyrosine kinase
c-Abl (38). Activated c-Abl promotes apoptosis through acti-
vation of downstream effectors such as the stress-activated
protein kinases (JNK and p38 MAP-kinases) (39), the tumour
suppressor p73 (40), and caspase 9 (41). As an inhibitor,
imatinib therefore has the potential to prevent apoptosis in
beta cells and indeed has been shown to protect islets
from pro-inflammatory cytokines through an NF-jB-
mediated pathway (36). Pre-treatment of the islets was
necessary for the protective effect, suggesting a pre-condi-
tioning effect of imatinib. Pre-conditioning of islets for islet
transplantation may protect islets against the initial inflam-
mation and hypoxia, which occurs immediately after islet
transplantation. The aim of the study was to investigate
whether pre-conditioning the islets for transplantation with
imatinib improved islet transplantation outcome.
Materials and methods
Animals
All mice were 8–10-week-old males sourced from Harlan
(Huntingdon, UK). Mice were housed in 12 h light/dark
cycles and had access to pelleted food and water ad libi-
tum. C57Bl/6 or ICR mice were used for islet isolation for
in vivo and in vitro experiments, respectively. To induce dia-
betes, C57Bl/6 mice were injected with 180mg/kg strepto-
zotocin (Sigma-Aldrich, Poole, UK) 5–7 days prior to islet
transplantation. Blood glucose concentrations were moni-
tored using Accu-Chek blood glucose meter and strips
(Accu-Chek Aviva, Roche Diagnostics, Burgess Hill, UK), and
mice with blood glucose concentrations over 20mM were
considered diabetic. All animal experiments were ethically
approved by our institution and were carried out under
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licence in accordance with the UK Home Office Animals
(Scientific Procedures) Act 1986.
Islet isolation
Islets were isolated using collagenase digestion and gradient
purification as previously described. Briefly, mice were killed
by cervical dislocation and the pancreatic duct was clamped at
the ampulla of Vater. A volume of 2mL of collagenase (Type
XI, 1mg/mL, Sigma-Aldrich) were injected into the pancreatic
duct before removal of the distended pancreas and incubation
for 10min at 37 C. Islets were purified from the pancreatic
digest using a Histopaque-1077 (Sigma-Aldrich) gradient. Islets
were washed and subsequently cultured in RPMI 1640 (Sigma-
Aldrich) supplemented with 10% foetal calf serum (FCS;
Sigma-Aldrich), 2mM L-glutamine, and antibiotics (100 units/
mL penicillinþ 100 ng/mL streptomycin; Sigma-Aldrich).
Cytokine treatment in vitro
Islets from ICR mice were pre-cultured for 24 h in the pres-
ence or absence of 10 lM imatinib (Selleckchem, Suffolk, UK)
prior to the exposure of the islets to 50U/mL IL-1b
(PeproTech, London, UK), 1,000 U/mL TNF-a (PeproTech), and
1,000U/mL IFN-c (PeproTech) for 24 hours. Apoptosis in the
islets was then measured by Caspase-Glo 3/7 (Promega,
Southampton, UK), and viability was measured by Cell-titer
Glo (Promega) which detects ATP.
Streptozotocin treatment in vitro
Islets from ICR mice were pre-cultured for 24 h in the presence
or absence of 10 lM imatinib prior to the exposure of the islets
to 1.5mM streptozotocin in serum-free RPMI media containing
5.6mM glucose. After 30min the islets were washed and
placed in normal culture conditions overnight (RPMI 1640 with
11.1mM glucose and 10% FCS). Apoptosis in the islets was
then measured by Caspase-Glo 3/7. Islet function was assessed
by measuring glucose-induced insulin secretion.
Glucose-induced insulin secretion
Insulin secretion was measured as previously described in
detail (18). Islets were pre-incubated for 2 h in RPMI media
containing 2mM glucose and 10% foetal calf serum. For each
experiment, eight to ten groups of three islets were picked
into 1.5mL Eppendorf tubes containing a bicarbonate-buf-
fered physiological salt solution, containing 2mM CaCl2 and
0.5mg/mL BSA with 2mM or 20mM glucose. The islets were
incubated at 37 C for 1 hour at each glucose concentration.
Supernatants were removed and frozen until insulin was
measured by an in-house radioimmunoassay (42).
Islet transplantation
Donor islets were isolated from C57Bl/6 mice and pre-cul-
tured in the presence or absence of 10 lM imatinib. A min-
imal mass of 200 islets were syngeneically implanted
under the kidney capsule of streptozotocin-diabetic C57Bl/6
recipients. Briefly, animals were anaesthetized using isoflurane
(1%–5% isoflurane, 95% oxygen). Buprenorphine, 30 lg/kg,
was administered as an analgesic at the start of surgery.
Once the animal was anaesthetized, an incision was made on
the left flank. The kidney was externalized and an incision
made in the kidney capsule. Islets were centrifuged into PE50
tubing (Becton Dickinson, Sparks, MD, USA), and a Hamilton
syringe (Fisher, Pittsburg, PA, USA) was used to deliver the
islets under the kidney capsule. Three series of transplant-
ation experiments were carried out. In the first experimental
series islets were pre-cultured for 3 days in the presence or
absence of 10 lM imatinib, and in the second experimental
series the islets were pre-cultured for 24 h in the presence or
absence of 10 lM imatinib. In both cases the mice were
monitored for 14 days. In the third experimental series, we
focused on the immediate post-transplantation period. Islets
were pre-cultured for 24 h in the presence or absence of
10 lM imatinib, and imatinib was also administered by gav-
age to the recipient mice (200mg/kg) 1 h prior to transplant-
ation and daily thereafter. The mice were killed, and the islet
graft-bearing kidneys were removed to measure insulin con-
tent as previously described (20).
Statistics
Data were analysed using Sigmaplot (Systat Software Inc.,
Hounslow, UK). Two groups were compared using an
unpaired t test, whereas three or more groups were analysed
using a one-way ANOVA. Blood glucose data were analysed
using two-way repeated measures (rm) ANOVA.
Results
Pre-treatment of islets with imatinib partially protects
islets from cytokine-induced damage in vitro
Pre-treatment of islets with 10 lM imatinib for 24 h partially
protected from cytokine-induced apoptosis (Figure 1A). In
addition, viability was increased in islets pre-treated with
10 lM imatinib prior to exposure to cytokines (Figure 1B).
Pre-treatment of islets with imatinib partially protects
islets from streptozotocin-induced damage in vitro
Pre-treatment of islets with 10 lM imatinib for 24 h partially
protected from streptozotocin-induced apoptosis (Figure 2A).
This was also shown to be protective against streptozotocin-
induced disruption to glucose-induced insulin release
(Figure 2B). Imatinib per se had no effect on glucose-induced
insulin secretion.
Pre-treatment of islets with imatinib does not affect islet
transplantation outcome
Pre-treatment of islets with imatinib for 3 days prior to trans-
plantation did not affect islet transplantation outcome
(Figure 3A). A similar pattern was seen when islets were
2 A. J. F. KING ET AL.
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pre-treated with imatinib for 24 h prior to islet transplantation
(Figure 3B).
Pre-treatment of islets with imatinib combined with
donor treatment transiently improved islet
transplantation outcome in the immediate
post-transplantation period
In a third transplantation series we pre-treated the islets with
imatinib for 24 h and also administered imatinib to the mice by
gavage. In these animals, there was significantly reduced blood
glucose concentrations in mice that received imatinib gavage
combined with imatinib pre-treated islets on the first 2 days
after implantation, but this effect was lost by day three (Figure
4A). Graft insulin content was not significantly different
between the treatments (Figure 4B). Mice gavaged with imati-
nib that did not receive an islet graft remained overtly diabetic.
Discussion
We have shown that pre-treatment of islets with imatinib par-
tially protected islets from both cytokine and streptozotocin-
induced damage in vitro. This is in agreement with previous
studies which have shown the ability of imatinib to inhibit
apoptosis in various cell types (43,44) including insulin-pro-
ducing cells (33,34,45). The mechanism may be dependent on
c-Abl rather than c-Kit, which is an alternative target of imati-
nib (34,46). Pre-incubation of islets with imatinib is necessary
to provide protection against streptozotocin, nitric oxide, and
cytokines, which indicates a state of preconditioning (33).
Exactly how imatinib promotes improved beta-cell survival is
not clear, but it has been proposed that altered signalling via
the JNK, ERK, PI3K, b-catenin, NF-jB, and PKCd signalling
pathways may alone, or in combinations, mediate the effects
of imatinib (33–36,45,47,48). Of these pathways, the NF-jB
and JNK pathways have been studied in relation to islet trans-
plantation outcome. Although short-term exposure of islets to
imatinib is associated with NF-jB activation, longer incubation
periods as used in the current study reduce NF-jB activation
in beta cells (36), leading to a lower sensitivity to cytokines.
While this effect was seen in the in vitro experiments, this did
not translate to improved islet transplantation outcomes in
our minimal mass transplantation model in mice. The effects
of NF-jB activation on islet transplantation outcome are
Figure 1. Islets pre-treated with imatinib are partially protected against cytokine-induced damage as shown by reduced levels of apoptosis (A) and increased ATP con-
tents (B). *P< 0.05 versus control; þP< 0.05 versus cytokines. One-way ANOVA, n¼ 5–8.
Figure 2. Islets pre-treated with imatinib are partially protected against streptozotocin-induced damage as shown by reduced levels of apoptosis (A) and retaining
glucose robust induced insulin secretion (B). A: *P< 0.05 versus control; þP< 0.05 versus cytokines; one-way ANOVA, n¼ 6–10. B: *P< 0.05 versus 2mM in respective
treatment group, t test, n¼ 7.
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ambiguous, with studies suggesting that acute inactivation
may be beneficial (49–51), whereas chronic inactivation may
be ineffective (52). The role of JNK in islet transplantation has
also been investigated. Inhibition of JNK during human or pig
islet isolation (53–55) and culture (54) improves transplant-
ation outcome in a mouse model.
One reason for the differing results in vivo compared with
in vitro could be that the in vitro environment does not
reflect the stresses that islets face in the post-transplantation
period. One important difference may be the levels of oxygen
available, which has previously been implicated as an import-
ant factor in islet NF-jB activation in response to transplant-
ation (49). Also it should be noted that only partial protection
was seen in vitro, which may not be sufficient to change the
outcome of transplantation. However, it is worth noting that,
although not reaching statistical significance, in every experi-
mental series the imatinib-treated islets performed marginally
better than the control islets, which may be indicative of a
subtle effect. This is similar to our previous study where inhib-
ition of NF-jB in islets prior to implantation using salicylate
had a subtle but non-significant effect (P< 0.072) (52).
However, subtle effects mediated by other pathways such as
JNK, ERK, beta-catenin, and PKCd cannot be ruled out. We
have previously noted that promising results in islets in vitro
do not always lead to improved function after transplantation;
for example, prevention of endothelial cell death in islets in
vitro did not improve islet transplantation outcome (19). One
factor which may be of importance is the ability of the pro-
tective compound to sustain beneficial effects after islet trans-
plantation. Although imatinib seems to be able to protect
islets in vitro after its removal, its ability to be effective in vivo
may require further exposure. Indeed, when we administered
imatinib to the mice immediately before and for 3 days after
implantation a significant improvement was seen in blood
glucose concentrations. However, this effect was lost by day
three, which is evident by no difference in insulin content of
the grafts upon removal.
We have previously improved islet transplantation out-
come by pre-treating the islets in vitro with either cells
(21,22) or compounds (24,56). Interestingly, these interven-
tions, which have been successful, have all improved glucose-
induced insulin secretion in the islets prior to transplantation.
It is perhaps not surprising that implanting well-functioning
islets may be the key to successful transplantation outcome.
Figure 3. Blood glucose concentrations of diabetic mice after transplantation of 200 islets pre-cultured with imatinib for 3 days (A) or 24 hours (B). Two-way rm
ANOVA, effect of imatinib P¼ 0.356 (A), and P¼ 0.358 (B). Effect of time P< 0.05 in (A) and (B); n¼ 5 (A) and n¼ 5–7 (B).
Figure 4. A: Blood glucose concentrations of diabetic mice after transplantation of 200 control-cultured islets or 200 islets pre-cultured with imatinib for 24 hours
combined with the recipient receiving imatinib by gavage. A separate group of non-transplanted animals received imatinib gavage. *P< 0.01 versus non-transplanted
imatinib gavage; þP< 0.05 versus control-cultured islet graft. Two-way rm ANOVA, n¼ 6–7. B: Insulin content of islet grafts on day three after transplantation.
P¼ 0.873, t test, n¼ 5–7.
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The superior outcome of islet transplantation outcome when
islets were only cultured for 1 day (Figures 3B and 4A) rather
than 3 days (Figure 3A) may also reflect this point, with cul-
tured islets losing beta cell mass. Although it has been well
documented that inflammation around the time of transplant-
ation leads to loss of a substantial amount of the islets
(57,58), pre-treatment of islets against inflammation may not
be sufficient to protect them against the harsh in vivo envir-
onment. We are therefore currently focusing on strategies
that will deliver anti-inflammatory agents to the site of
implantation. To do this we have applied a layer-by-layer
nanoencapsulation method which can incorporate anti-inflam-
matory peptides such as a1-anti-trypsin (59). It is possible
that this strategy combined with using insulinotropic peptides
will lead to better function and survival of islets in a trans-
plantation setting.
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